Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

2301studies shown

Showing 577-588 of 2,301

CompletedNCT00377299

Citicoline add-on Therapy for depression

This study is completed in the United States. It is testing Citicoline add-on Therapy for depression.

In United States

Why is this study shown?

This study is directly about Depression.

Depression, BipolarityBehavioralFrom 18 Years to 70 Years

Countries: United States
Sponsor: University of Texas Southwestern Medical Center
Condition: Depression, Bipolarity

View study

CompletedNCT04504253

A Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionOtherFrom 18 Years to 99 Years

Countries: United States
Sponsor: University of Utah
Condition: Depression

View study

CompletedNCT00095758

Adjunctive Aripiprazole in people with Major Depressive Disorder

This study is completed in the United States. It is testing aripiprazole for depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Depression

View study

CompletedNCT00105196

Aripiprazole in people with Major Depressive Disorder

This study is completed in the United States. It is testing aripiprazole for depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Depression

View study

CompletedNCT04103892

CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

This study is completed in the United States. It is testing CLE-100 (Oral Esketamine) for depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Clexio Biosciences Ltd.
Condition: Depression

View study

Active Not RecruitingNCT06254612

SP-624 for depression

This study is active but not recruiting in the United States. It is testing SP-624 for depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Sirtsei Pharmaceuticals, Inc.
Condition: Depression

View study

CompletedNCT04479852

Safety and Efficacy of SP-624 for depression

This study is completed in the United States. It is testing Safety and Efficacy of SP-624 for depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Sirtsei Pharmaceuticals, Inc.
Condition: Depression

View study

CompletedNCT06267846

NBI-1070770 for depression

This study is completed in the United States. It is testing NBI-1070770 for depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Neurocrine Biosciences
Condition: Depression

View study

CompletedNCT06570369

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

This study is completed in the United States. It focuses on depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 60 Years

Countries: United States
Sponsor: Sirtsei Pharmaceuticals, Inc.
Condition: Depression

View study

CompletedNCT05593029

A study of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand what a therapy or guided support program could change in day-to-day care and decision-making.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States, Canada, Bulgaria, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Depression

View study

TerminatedNCT03643159

A study to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolarity type I, and Major Depressive Disorder

This study was terminated in the United States. It focuses on depression.

Remote / online

Why is this study shown?

This study is directly about Depression.

Depression, Bipolarity, ...DrugFrom 18 Years to 63 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Depression, Bipolarity, ...

View study

CompletedNCT05061719

Lumateperone for depression

This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing lumateperone for depression.

In United States

Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years

Countries: United States, Bulgaria, Czechia, ...
Sponsor: Intra-Cellular Therapies, Inc.
Condition: Depression

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.